915922-85-9

Basic information

• Product Name: (1-ethylpiperidin-4-yl)acetic acid(SALTDATA: 0.5HCl)
• Synonyms: (1-ethylpiperidin-4-yl)acetic acid(SALTDATA: 0.5HCl);2-(1-ethyl-4-piperidinyl)acetic acid;2-(1-ethyl-4-piperidyl)acetic acid;2-(1-ethylpiperidin-4-yl)ethanoic acid;1-ethyl-4-piperidineacetic acid;(1-ETHYLPIPERIDIN-4-YL)ACETIC ACID HCL;(1-ethyl-4-piperidinyl)acetic acid;2-(1-ethylpiperidin-1-ium-4-yl)acetate
• CAS NO: 915922-85-9
• Molecular Formula: C9H17NO2
• Molecular Weight: 171.23678
• Mol File: 915922-85-9.mol

Chemical Properties

• Boiling Point: 285.9±13.0 °C(Predicted)
• Appearance: /
• Density: 1.023±0.06 g/cm3(Predicted)
• PKA: 4.49±0.10(Predicted)
• CAS DataBase Reference: (1-ethylpiperidin-4-yl)acetic acid(SALTDATA: 0.5HCl)(CAS DataBase Reference)
• NIST Chemistry Reference: (1-ethylpiperidin-4-yl)acetic acid(SALTDATA: 0.5HCl)(915922-85-9)
• EPA Substance Registry System: (1-ethylpiperidin-4-yl)acetic acid(SALTDATA: 0.5HCl)(915922-85-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 915922-85-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
(1-ethylpiperidin-4-yl)acetic acid(SALTDATA: 0.5HCl) is used as a pharmaceutical intermediate for its potential role in the development of new drugs and treatment options. Its unique structure and properties make it a valuable building block in the synthesis of various medicinal compounds.
Used in Organic Synthesis:
In the field of organic synthesis, (1-ethylpiperidin-4-yl)acetic acid(SALTDATA: 0.5HCl) serves as a key component in the creation of complex organic molecules. Its reactivity and functional groups allow for a wide range of chemical reactions, facilitating the synthesis of diverse organic compounds for various applications.
Used in Drug Development:
As a pharmaceutical intermediate, (1-ethylpiperidin-4-yl)acetic acid(SALTDATA: 0.5HCl) is utilized in drug development to explore its potential therapeutic effects and mechanisms of action. Its incorporation into drug molecules may contribute to the discovery of novel treatments for various diseases and conditions.
Used in Chemical Stability Enhancement:
The addition of hydrochloric acid in the salt form of (1-ethylpiperidin-4-yl)acetic acid(SALTDATA: 0.5HCl) enhances the stability of the compound, making it more suitable for use in various chemical processes and applications. This stability is crucial for the compound's performance and longevity in different environments and conditions.

Upstream product

• 1379341-39-5 (1-ethylpiperidin-4-yl)acetonitrile 
• 1247227-36-6 (1-ethylpiperidin-4-ylidene)acetonitrile 
• 3612-18-8 N-ethyl-4-piperidone 

Relevant articles and documents

Synthesis and pharmacological evaluation of indolinone derivatives as novel ghrelin receptor antagonists

The ghrelin receptor is a G-protein-coupled receptor (GPCR) widely expressed in the brain, stomach and the intestine. It was firstly identified during studies aimed to find synthetic modulators of growth hormone (GH) secretion. GHSR and its endogenous ligand ghrelin were found to be involved in hunger response. Through food intake regulation, they could affect body weight and adiposity. Thus GHSR antagonists rapidly became an attractive target to treat obesity and feeding disorders. In this study we describe the biological properties of new indolinone derivatives identified as a new, chiral class of ghrelin antagonists. Their synthesis as well as the structure-activity relationship will be discussed herein. The in vitro identified compound 14f was a potent GHSR1a antagonist (IC50 = 7 nM). When tested in vivo, on gastric emptying model, 14f showed an inhibitory intrinsic effect when given alone and it dose dependently inhibited ghrelin stimulation. Compound 14f also reduced food intake stimulated both by fasting condition (high level of endogenous ghrelin) and by icv ghrelin. Moreover this compound improved glucose tolerance in ipGTT test.

INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF

The present invention relates to 3-disubstituted indol-2-one derivatives, to their preparation and to their therapeutic application.

Heterocyclic compouds

A compound of the general formula wherein: n is 0 or 1; M1 is an amino group; Q is an aromatic heterocyclic group containing a basic nitrogen atom; M2 is an imino group; L is a template group; and A is an acidic group, or an ester or amide derivative thereof, or a sulphonamide group; and pharmaceutically acceptable salts and pro-drugs thereof, for use in the treatment of a disease in which platelet aggregation mediated by the binding of adhesion molecules to GPIIb-IIIa is involved. Novel compounds are also disclosed.